AiViva at Biocom California
2025-02-25 - 2025-02-27 | The Lodge at Torrey Pines, 11480 N. Torrey Pines Road, La Jolla, CA, 92037, United States
AiViva attending Global Life Science Partnering & Investor Conference presented by Biocom California. Location in beautiful LaJolla, California.
Dates of event: February 25-27, 2025

AiViva at #AAD2025
2025-03-07 - 2025-03-11 | Orange County Convention Center, 9800 International Drive, Orlando, FL, 32819, United States
Darlene Deecher, Vice President, Clinical Development, will be speaking at the American Academy of Dermatology (AAD) Annual Meeting on March 7-11, 2025 in Orlando, Florida.
AAD is the largest, most influential, and representative dermatology group in the United States. It is also the premier dermatology education event of the year led by dermatology experts and the best time to connect with peers and industry leaders. For more information: https://www.aad.org/member/meetings-education/am25
If you’d like to connect with Dr. Deecher, feel free to contact her for an appointment at AAO: darlene@aiviva.com

Join AiViva BioPharma at LSI USA Summit 2025
2025-03-17 - 2025-03-21 | CA
AiViva partnering with industry-leading executives building Medtech, from emerging companies, venture capital and private equity firms to family offices and small business.
March 17th – 21st in Dana Point, CA

AiViva Virtual Partnering with RESI EUROPE 2025
2025-04-01 - 2025-04-03 | CA
AiViva excited to attend workshops and meetings related to Biotech, MedTech, healthcare innovation, cutting-edge technologies and regulatory challenges shaping the industry on how it impacts patient care.
If you wish to contact Shane Cerrato, Vice President, Business Development, you may contact him at: shane@aiviva.com
Learn more at: https://resiconference.com/

AiViva BioPharma at ARVO
2025-05-04 - 2025-05-08 | CA
AiViva BioPharma is excited to present posters at The Association for Research in Vision & Ophthalmology (ARVO) conference in Salt Lake City, Utah on May 6, 2025.
Presentation Number – Posterboard Number: 3782 – B0003 Translation
Abstract/Presentation Title: Periocular Administration of AIV007 Demonstrates Depot Formation for Prolonged Drug Release in Rabbits and Humans
Presentation Type: Poster Session
Session Number: 363
Session Title: Diabetic Macular Edema. Clinical Research
Session Date/Times: May 6, 2025 from 3:30 PM to 5:15 PM

Presentation Number – Posterboard Number: 3783 – B0004 CLIN Translation
Abstract/Presentation Title: Periocular Administration of AIV007 in the Treatment of Diabetic Macular Edema: Preliminary Phase 1 Trial Results
Presentation Type: Poster Session
Session Number: 363
Session Title: Diabetic Macular Edema. Clinical research
Session Date/Times: May 6, 2025 from 3:30 PM to 5:15 PM

If you attend ARVO 2025, please stop by and say hello! We look forward to meeting you.

AiViva is heading to BIO International 2025
2025-06-16 - 2025-06-19 | CA
We’re excited to announce that AiViva BioPharma will participate in the BIO International Convention 2025, which will take place this June in Boston!
With three clinical-stage programs and our proprietary JEL® long-acting injectable platform, AiViva is redefining how therapies are delivered. It focuses drugs precisely where needed, minimizing systemic exposure, and extending duration for up to six months. Our pipeline targets multi-billion-dollar markets across oncology, ophthalmology, and dermatology, with accelerated 505(b)(2) regulatory paths and IP protection into the 2040s.
We’re actively scheduling partnering meetings with investors, pharma partners, and innovators looking to collaborate.
Let’s meet in Boston and shape the next wave of targeted, long-acting therapies.
Agustin de la Calle, Vice President of Business Development:

https://www.linkedin.com/in/agustin-de-la-calle-4b0136/
office@aiviva.com

AiViva Attending OIS 2025
2025-07-29 | CA
AiViva attending the 2025 OIS RETINA INNOVATION SUMMIT, located in Long Beach, California.
Date of event is July 29, 2025.

AiViva Presenting at OIS 2025 - San Diego, CA
2025-11-21 - 2025-11-22 | CA
Where collaboration is driven by a deep sense of commitment to learn and share game-changing therapies in ophthalmology, Ophthalmology Innovation Source (OIS) gives the opportunity to network where extraordinary things happen when the right people connect!
Join AiViva at OIS as our CEO, Dr. Diane Tang-Liu, as she presents “AIV007 in nAMD and DME Results” on Saturday, November 22, 2025.
Diane and our Head of Business Development, Agustin de la Calle, will be happy to meet you at this networking event. If you are interested in meeting these two dynamic executives, reach out to Agustin at agustindlc@aiviva.com.
For more information on OIS: Ophthalmology Innovation Source

To listen to Dr. Tang-Liu’s 2024 OIS speaking event, click here:

2024 OIS Presentation Recording by Dr. Diane Tang-Liu, CEO *

∗ Disclaimer: Investigational product; early-stage data; not for promotional use.

AiViva Presenting at ATF 2026 Powered by Octane
2026-01-08 - 2026-01-09 | CA
AiViva BioPharma is pleased to join Octane Aesthetics Tech Forum this January 8–9, 2026 in Newport Beach as a Presenting Company. Diane Tang-Liu, CEO and President, is AiViva’s representative as well as Agustin de la Calle, Vice President of Business Development.
We look forward to discussions around AIV001, a clinical-stage dermatology program currently under evaluation in Phase I/IIa clinical studies.
In Phase I/IIa clinical studies, AIV001 is being evaluated as an investigational dermatology program in indications related to fresh and established scar modulation and exploratory approaches to surgical-free management of low-risk basal cell carcinoma (BCC), with assessments including safety, tolerability, histologic findings, and cosmetic outcomes.
Contact Agustin for appointments to meet with this dynamic duo: agustindlc@aiviva.com
https://www.octane-oc.org/event/atf2026/agenda
www.aiviva.com

UPDATE:
To listen to Dr. Tang-Liu’s 2026 ATF speaking event, click on link below:

2026 ATF Presentation Recording by Dr. Diane Tang-Liu, CEO *

∗ Disclaimer: Investigational product; early-stage data; not for promotional use.
